Global Study evaluating RLY-2608 + fulvestrant + atirmociclib (CDK4i) in PI3Ka-mutated HR+/HER2- metastatic breast cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atirmociclib (Primary) ; Fulvestrant (Primary) ; Ribociclib (Primary) ; RLY-2608 (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions

26 Feb 2025 According to a Relay Therapeutics media release, company initiated triplet cohort for RLY-2608 + fulvestrant + atirmociclib combination.
09 Sep 2024 According to a Relay Therapeutics media release, company will initiate RLY-2608 + atirmociclib (CDK4) + fulvestrant triplet by the end of 2024.
06 Aug 2024 According to a Relay Therapeutics media release, the company announced global clinical trial collaboration with Pfizer to evaluate atirmociclib in combination with RLY-2608 and fulvestrant in patients with PI3Ka-mutant, HR+, HER2- metastatic breast cancer. This trial is planned to start by end of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com